Hennepin Healthcare announced Monday it will halt a clinical trial on ketamine following criticism over the hospital enrolling patients before getting consent.
The use of the sedative, administered to agitated patients by paramedics during emergency calls, is already the subject of outside reviews commissioned by the hospital and the city of Minneapolis.
"Hennepin Healthcare would never conduct research without appropriate consent from patients involved," hospital spokeswoman Christine Hill said in a statement Monday evening.
"However, due to the concerns that have been expressed we have decided to put the study on hold at this time. In addition, we are committed to a much higher level of transparency and community dialogue, well beyond the federal regulations."
Earlier Monday, state Sen. Jeff Hayden and Hennepin County Commissioner Peter McLaughlin called the county hospital's clinical trial "unconscionable and unethical."
"While we understand Hennepin Healthcare claims it has followed federal research procedures, we believe an urban hospital that treats a large number of people of color and low-income Minnesotans must take extra care," said the statement from Hayden, DFL-Minneapolis, and McLaughlin.
"Anything less disregards the history of maltreatment for these communities as test subjects for new drugs and medical procedures. This is unacceptable. We can — and must — do better."
The Hennepin County Board has asked Hennepin Healthcare to appear at a meeting Tuesday and provide a report on the study. The developments Monday came a day after a Star Tribune story about the hospital's ketamine research.